【东方证券】和黄医药首次覆盖报告：Pipeline开花结果，出海正兑现.pdf

境内恢复领先同行，Pipeline环比明显提升

To further expand mRNA and ADC pipelines

2022H1收入+46.83%，归母净利+41.21%，批产产品加速放量，新型号Pipeline持续拓展

连续获批版号，强化2023年Pipeline确定性

Reaccelerate on strong pipeline in FY23E

EVIF Project Pipeline - August 2024

Rosy pipeline ahead, non-game segments improving

Moving into 3Q23E strong pipeline

Clinical development of core pipeline products continues

（中英文）美国如何拆除北溪管道How America Took Out The Nord Stream Pipeline